Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 5 - Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof
Patents for C07K 5 - Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof (30,692)
12/2005
12/22/2005WO2005121354A2 Peptide substrates recognisable by a botulinum toxin a, bont/a and the use thereof
12/22/2005WO2005121167A1 Monocyte locomotion inhibitory factor
12/22/2005WO2005120564A2 Vaccine compositions and methods
12/22/2005WO2005077931A3 Method for the production of 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine
12/22/2005US20050282882 Diamines as modulators of chemokine receptor activity
12/22/2005US20050282743 Molecular interactions in cells
12/22/2005US20050282742 Such as bortezomib, by freeze drying
12/22/2005US20050282741 Peptides and their use to ameliorate cell death
12/22/2005DE102004026103A1 Trimere makrocyclisch substituierte Aminoisophthalsäure-Halogen-Benzolderivate Trimeric macrocyclic substituted aminoisophthalic-halo-benzene derivatives
12/22/2005DE10005932B4 Peptide und deren Verwendung in einem Verfahren zur Diagnostik von Zöliakie und Dermatitis herpetiformis Peptides and their use in a method for the diagnosis of celiac disease and dermatitis herpetiformis
12/22/2005CA2569909A1 Vaccine compositions and methods
12/22/2005CA2565678A1 Peptide substrates recognisable by a botulinum toxin a, bont/a and the use thereof
12/21/2005EP1607384A1 Novel functional peptide nucleic acid and process for producing the same
12/21/2005EP1606305A2 Nucleic acid compounds for inhibiting angiogenesis and tumor growth
12/21/2005EP1605969A1 Angiotensin-converting enzyme inhibitory peptides
12/21/2005EP1605963A2 Inhibitors of antigen presentation by mhc class ii molecules and methods of use thereof
12/21/2005EP1605961A2 Polypeptide compounds for inhibiting angiogenesis and tumor growth
12/21/2005EP1265930A4 Cyclodextrin dimers with spacers having peptide structures for encapsulation of pharmaceutically active substances with potential high side-effects
12/21/2005EP0973796B1 Method for preparing and purifying an n-alkylated aspartame derivative
12/21/2005CN1232507C Growth hormone secretagogues
12/20/2005US6977264 For therapy and prophylaxis of obesity, diabetes
12/20/2005US6977256 Compounds and compositions as cathepsin S inhibitors
12/20/2005US6977241 SH2 domain binding inhibitors
12/20/2005US6977150 Process and compositions for peptide, protein and peptidomimetic synthesis
12/15/2005WO2005118621A2 Omi pdz modulators
12/15/2005WO2005118620A2 Methods for preparing internally constraied peptides and peptidomimetics
12/15/2005WO2005118619A1 Dipeptide exhibiting antihypertensive action
12/15/2005WO2005118618A1 Substituted propane phosphinic acid derivatives
12/15/2005WO2005118613A2 Antibacterial amide macrocycles
12/15/2005WO2005118527A2 Fluorous capping reagents, and methods for peptide purification
12/15/2005WO2005117940A2 Cell death modulation via antagonists of fasl and fas activation
12/15/2005WO2005056572A3 Clustered multi-antigenic carbohydrate constructs, methods for their preparation and uses thereof
12/15/2005WO2005033267A3 Antigens targeted by prevalent pathogenic t cells in type 1 diabetes and uses thereof
12/15/2005WO2004083258A3 Branched water-soluble polymers and their conjugates
12/15/2005WO2002083921A8 Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
12/15/2005US20050277583 Histone deacetylase inhibitors and process for producing the same
12/15/2005DE102004025731A1 Antibakterielle Amid-Makrozyklen III Antibacterial amide macrocycles III
12/15/2005CA2563691A1 Cell death modulation via antagonists of fasl and fas activation
12/15/2005CA2558963A1 Omi pdz modulators
12/14/2005EP1604032A2 Method for detecting prognosis of cancer
12/14/2005EP1261583B1 INHIBITORS OF THE ICE/Ced-3 FAMILY OF CYSTEINE PROTEASES
12/14/2005CN1708509A Composition for the treatment of infection by flaviviridae viruses
12/13/2005US6974884 Improved methods for synthesis of phosphinothiol reagents and novel protected reagents for use in peptide ligation
12/13/2005US6974876 Method for preparing intermediates useful in synthesis of retroviral protease inhibitors
12/13/2005US6974836 Diamines as modulators of chemokine receptor activity
12/13/2005US6974809 Inhibitors of interleukin 1-β converting enzyme
12/08/2005WO2005116656A1 Identification of compounds modifying a cellular response
12/08/2005WO2005116643A2 Identification of compounds modifying a cellular response
12/08/2005WO2005116068A1 Peptides or peptidic conjugate derivatives of msh and the use thereof for cosmetically fighting against canities
12/08/2005WO2005116067A2 Msh-agonist tripeptide conjugates
12/08/2005WO2005116055A1 Peptides, antibodies and compositions containing same useful for treating hiv virus infection
12/08/2005WO2005116053A1 Novel hair growth stimulant
12/08/2005WO2005115997A1 Trimeric macrocyclic substituted aminoisophthalate halophenyl derivatives
12/08/2005WO2005115174A2 Alpha-msh-antagonist didpeptide conjugates
12/08/2005WO2005115149A2 Insectidal activity of a cyclic peptide
12/08/2005WO2005097828A3 Peptides of cav2.2 that inhibit pain
12/08/2005WO2005041882A3 Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
12/08/2005WO2004093798A3 Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors
12/08/2005US20050272798 Analogues of rachelmycin and the duocarmycins that are potent cytotoxins containing a benzodipyrrole or naphthopyrrole ring; anticancer agents
12/08/2005US20050272780 Small molecule inhibitors of rotamase enzyme activity
12/08/2005US20050272710 Providing sustained systemic concentrations of therapeutic or prophylactic agents such as gamma-aminobutyric acid derivatives following oral adiminstration to animals
12/08/2005US20050272668 Anti-inflammatory compositions and methods
12/08/2005US20050272664 Methods for inhibiting angiogenesis and or lymphangiogenesis
12/08/2005US20050272663 Novel substituted prolines as inhibitors of hepatitis C virus NS3 serine protease
12/08/2005US20050271655 Nogo receptor antagonists
12/08/2005CA2609558A1 Identification of compounds modifying a cellular response
12/08/2005CA2568168A1 Identification of compounds modifying a cellular response
12/08/2005CA2566481A1 Peptides or peptidic conjugate derivatives of msh and the use thereof for cosmetically fighting against canities
12/08/2005CA2566478A1 Alpha-msh-antagonist didpeptide conjugates
12/08/2005CA2565805A1 Msh-agonist tripeptide conjugates
12/07/2005EP1602719A1 Control of transglutaminase catalyzed protein modification by selective irreversible transglutaminase inhibitors
12/07/2005EP1601685A1 Hepatitis c inhibiting compounds
12/07/2005CN1705647A Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
12/07/2005CN1705639A Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors
12/06/2005US6972341 Prodrugs of GABA analogs, compositions and uses thereof
12/06/2005US6972328 can comprise DNA, RNA, PNA, or any combination or chimera thereof
12/06/2005US6972282 Process for producing a product containing antihypertensive tripeptides
12/06/2005US6972281 Histogranin-like peptides and non-peptides, processes for their preparation and uses thereof
12/06/2005CA2362834C Modulators of beta-amyloid peptide aggregation comprising d-amino acids
12/06/2005CA2096528C Retroviral protease inhibitors
12/05/2005WO2005116054A1 Process for preparing acyclic hcv protease inhibitors
12/05/2005CA2568008A1 Process for preparing acyclic hcv protease inhibitors
12/01/2005WO2005113582A1 Substituted ethane-1,2-diamines for the treatment of alzheimer's disease
12/01/2005WO2005113581A1 Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease
12/01/2005WO2005113580A1 Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
12/01/2005WO2005113579A1 Bacterial efflux pump inhibitors and methods of treating bacterial infections
12/01/2005WO2005113471A1 Method of labeling with isotope of oxygen
12/01/2005WO2005112971A1 Method for inhibiting angiogenesis and/or lymphangiogenesis
12/01/2005WO2005095403A3 Macrocyclic compounds as inhibitors of viral replication
12/01/2005WO2005090383A3 Process for preparing macrocyclic dipeptides which are suitable for the treatment of hepatitis c viral infections
12/01/2005WO2005077969A3 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
12/01/2005US20050267214 Containing a quinolinecarbonylalkyl group, e.g., N1-[3-[(butylamino)sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl) amino]butanediamide
12/01/2005US20050267171 Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
12/01/2005US20050267151 Hepatitis C; preparing 8-bromo-7-alkoxyquinolines 2-substituted with a hetercyclic ring having an amine, carbamate, amine or urea group an 4-substituted with a 3-prolineoxy- group or derivative; intermediates
12/01/2005US20050267150 Treating Alzheimer's disease with substituted urea or thiourea-alkylamidolactone compound
12/01/2005US20050267044 Novel compounds and compositions as cathepsin S inhibitors
12/01/2005US20050267043 Novel inhibitors of hepatitis C virus NS3 protease
12/01/2005US20050267041 Tetrapeptide derivative crystals
12/01/2005US20050267040 Hepatitis C virus inhibitors
12/01/2005US20050267039 IL-16 antagonists
1 ... 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 ... 307